For families navigating an ALS diagnosis, the daily reality is a race against the progressive hardening of muscles and the relentless loss of motor function. While modern medicine has largely focused on palliative care and marginal life extension, a new set of long-term clinical data is challenging the status quo, offering a potential breakthrough in how we manage Amyotrophic Lateral Sclerosis.

Masitinib Treatment Yields 42.3% Five-Year Survival Rate

AB Science recently published long-term survival data on medRxiv regarding Masitinib, a tyrosine kinase inhibitor designed to block intracellular signaling pathways that trigger inflammation and cell death. The analysis focused on 130 patients who participated in the AB10015 phase 2b/3 clinical trial. The results indicate that patients administered a daily dose of 4.5mg/kg of Masitinib achieved a 5-year survival rate of 42.3% post-diagnosis. This figure climbed to 52.9% among patients who had not yet reached a state of complete functional impairment. When measured against the company’s historical control group—which reflects standard survival statistics in existing treatment environments at 23.5%—the data suggests a significant shift in patient outcomes.

Extending Median Survival by 79 Months

The true impact of the drug becomes clear when comparing the clinical results against established prognostic models. The European Network for the Cure of ALS (ENCALS) survival prediction model estimated a median survival duration of 42 months for this patient cohort. However, the actual observed median survival for those treated with Masitinib reached 121 months. This represents an additional 79 months of life, a substantial deviation from the expected progression of the disease. Beyond the raw survival numbers, the quality of life metrics are equally compelling; 49% of the long-term survivors maintained their independence without the need for mechanical respiratory support.

These findings have provided the momentum for AB Science to initiate the AB23005 confirmatory clinical trial, which will enroll 408 patients. This study will utilize a randomized, double-blind design to compare a combination therapy of Masitinib and Riluzole against a control group receiving Riluzole and a placebo. By inhibiting the abnormal activity of microglia and mast cells, Masitinib aims to fundamentally slow the neurodegenerative cascade that defines ALS.

Patients are moving toward a future where treatment focuses on preserving daily life rather than merely slowing the inevitable decline.